Literature DB >> 17845896

Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.

Aydin Yilmaz1, Dilek Ernam, Ebru Unsal, Funda Demirag, Sükran Atikcan, Irfan Taştepe.   

Abstract

BACKGROUND: Angiogenesis is an early step in tumor progression, and vascular endothelial growth factor (VEGF) is an important angiogenic factor. In this study, we investigated the prognostic significance of VEGF immunostaining in tumor tissues of non-small cell lung cancer (NSCLC) patients during a 5-year follow-up period.
METHODS: The study comprised 50 male patients diagnosed with NSCLC with a mean age of 57.26 +/- 8.64 years (range: 40-74 years). All patients had early stage NSCLC and none of the patients received chemo- or radiation therapy before surgery. VEGF immunostaining was performed in tumor tissues and immunoreactivity was graded as negative (0-10%), weak (10-50%), and strong (>50% tumors are stained).
RESULTS: VEGF staining was weak in 20 (40%) specimens and strong in 13 (26%) specimens, whereas VEGF staining was negative in 17 (34%) specimens. Strong VEGF staining showed a significant correlation with both short time of relapse (p = 0.0001) and short survival (p = 0.0005). Multivariate analysis using Cox regression model was performed to determine the independent prognostic factors. Age (p = 0.029, OR: 1.05), tumor stage (p = 0.001, OR: 14.89), and VEGF staining (p = 0.006, OR: 4.65) were all found as independent prognostic factors in NSCLC.
CONCLUSIONS: Strong VEGF immunostaining in tumor tissues was found to be an important prognostic factor for time to relapse and survival in patients with early stage disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845896     DOI: 10.1016/j.arcmed.2007.04.005

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  6 in total

1.  Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.

Authors:  Ahmet Bircan; Sema Bircan; Nilgun Kapucuoglu; Necla Songur; Onder Ozturk; Ahmet Akkaya
Journal:  Pathol Oncol Res       Date:  2010-03-28       Impact factor: 3.201

Review 2.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

3.  Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.

Authors:  María J Pajares; Jackeline Agorreta; Marta Larrayoz; Aurélien Vesin; Teresa Ezponda; Isabel Zudaire; Wenceslao Torre; María D Lozano; Elisabeth Brambilla; Christian Brambilla; Ignacio I Wistuba; Carmen Behrens; Jean-Francois Timsit; Ruben Pio; John K Field; Luis M Montuenga
Journal:  J Clin Oncol       Date:  2012-02-21       Impact factor: 44.544

4.  Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo.

Authors:  Dana M Brantley-Sieders; Guanglei Zhuang; David Vaught; Tanner Freeman; Yoonha Hwang; Donna Hicks; Jin Chen
Journal:  Mol Cancer Res       Date:  2009-05-12       Impact factor: 5.852

5.  Expression of livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma.

Authors:  Li Chen; Guo-Sheng Ren; Fan Li; Shan-Quan Sun
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

6.  Vascular endothelial growth factor in children with neuroblastoma: a retrospective analysis.

Authors:  Gordana Jakovljević; Srana Culić; Jasminka Stepan; Aleksandra Bonevski; Sven Seiwerth
Journal:  J Exp Clin Cancer Res       Date:  2009-11-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.